Comparative Effects of Lanthanum Carbonate and Calcium Carbonate on Renal Osteodystrophy in Patients with End-Stage Renal Disease
نویسندگان
چکیده
_______________________________ Correspondence to: Goce B Spasovski, MD, PhD, Department of Nephrology, Clinical Center Skopje, Vodnjanska 17, 1000 Skopje, Macedonia, Fax: +389 2 3220 935 or +389 2 3231 501, E-mail: [email protected] Comparative Effects of Lanthanum Carbonate and Calcium Carbonate on Renal Osteodystrophy in Patients with End-Stage Renal Disease G.B. Spasovski , A. Sikole, S. Gelev, J. Masin-Spasovska, T. Freemont, I. Webster, M. Gill, C. Jones, P. C. D'Haese, M.E. De Broe Department of Nephrology, University of Skopje, Macedonia; Osteoarticular Pathology, The Medical School, University of Manchester, UK; Shire Pharmaceuticals Group plc, Basingstoke, UK; Department of Nephrology-Hypertension, University of Antwerp, Belgium
منابع مشابه
Improving phosphate-binder therapy as a way forward.
Aluminium- or calcium-based phosphate-binding agents traditionally have been used to treat hyperphosphataemia in patients with end-stage renal disease. Although these agents effectively lower serum phosphorus levels, they are associated with serious side effects. Aluminium-based agents are associated with bone toxicity, renal osteodystrophy and encephalopathy, and calcium-based agents increase ...
متن کاملPA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure
The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated. Rats with adenine-induced chronic renal failure (CRF) were prepared by feeding them an adenine-containing diet for four weeks. They were also freely fed a diet that contained PA21 ...
متن کاملReducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
BACKGROUND The majority of patients with end-stage renal disease on dialysis are hyperphosphataemic. Lanthanum carbonate has been shown to be a highly effective phosphate binder in pre-clinical studies. A 4-week, open-label, dose-titration trial was conducted to assess the ability of lanthanum carbonate to control phosphate levels in patients with chronic renal failure. METHODS This prelimina...
متن کاملSevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease
Endothelial dysfunction underlies multiple cardiovascular consequences of chronic kidney disease (CKD) and antecedent diabetes or hypertension. Endothelial insults in CKD or end-stage renal disease (ESRD) patients include uremic toxins, serum uric acid, hyperphosphatemia, reactive oxygen species, and advanced glycation endproducts (AGEs). Sevelamer carbonate, a calcium-free intestinally nonabso...
متن کاملEffects of treatment of renal osteodystrophy on bone histology.
Renal osteodystrophy is characterized by abnormalities in bone turnover, mineralization, and bone volume. The effects of treatment modalities for renal osteodystrophy on bone should be analyzed with respect to these abnormalities. The major treatment modalities for renal osteodystrophy include phosphate binders, vitamin D compounds, and calcimimetics. Aluminum-containing phosphate binders have ...
متن کامل